Maven leaving revenue on table

This is the core tradeoff in Maven’s model, it scales distribution and care coordination fast, but it does not own the highest dollar parts of fertility care. Maven can sell employers software, navigation, virtual consults, and benefits administration, but when a member needs an IVF cycle, lab work, medications, or surrogacy, much of that spend still flows to partner clinics and outside vendors instead of staying inside Maven’s own system.

• Maven has built more control than a pure referral marketplace. It now runs Maven Wallet, negotiates rates through a performance managed clinic network, and steers members into in network clinics. But it still does not own the clinic, lab, or pharmacy assets themselves, so its take rate is naturally capped.
  1 sacra 4 mavenclinic 5 mavenclinic 6 mavenclinic
• Kindbody captures more of each fertility dollar because the same company can do the consult, ultrasound, egg retrieval, IVF lab work, genetic testing through Kindlabs, and surrogacy through its in house program. That is why vertical integration can support materially higher gross margins, even when sticker prices are lower for patients.
  2 sacra 7 kindbody 8 kindbody
• Progyny shows the middle ground. It is also asset light, but more deeply embedded in claims, pharmacy, and benefit design at very large scale. Maven’s answer has been to move beyond fertility into maternity, pediatrics, and menopause, so it can earn across a longer family health relationship even if it earns less on each fertility procedure.
  1 sacra 3 sacra 9 progyny

The next phase is a race between breadth and ownership. Maven is pushing breadth, across 28 million lives, 175 plus countries, and more life stages, while adding tighter network control and benefits administration. Integrated players are pushing ownership, by pulling clinics, labs, and adjacent services under one roof. The winners will be the companies that can pair lower total cost with a simpler patient journey.